
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1588567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nature Reviews Nephrology, 2019, 15, 275-289.	9.6	609
2	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. JAMA - Journal of the American Medical Association, 2012, 307, 674.	7.4	495
3	First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 770-775.	3.6	395
4	Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. Circulation, 2011, 124, 940-950.	1.6	311
5	Calciphylaxis. New England Journal of Medicine, 2018, 378, 1704-1714.	27.0	286
6	Treatment of hepatitis C virus–associated mixed cryoglobulinemia with directâ€acting antiviral agents. Hepatology, 2016, 63, 408-417.	7.3	226
7	Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal of the American Society of Nephrology: JASN, 2016, 27, 903-913.	6.1	213
8	Patients with Fabry disease on dialysis in the United States. Kidney International, 2002, 61, 249-255.	5.2	172
9	Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation, 2016, 133, 518-536.	1.6	149
10	Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus. Diabetes Care, 2016, 39, 1052-1055.	8.6	142
11	Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 105-116.	2.5	125
12	Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 2014, 64, 1005-1011.	2.7	106
13	Therapeutic Effects of Vitamin D Analogs on Cardiac Hypertrophy in Spontaneously Hypertensive Rats. American Journal of Pathology, 2010, 177, 622-631.	3.8	94
14	Insulin Resistance and Alterations in Angiogenesis. Hypertension, 2004, 43, 988-992.	2.7	93
15	Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1899.	7.4	77
16	Cohort Studies: Marching Forward. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1117-1123.	4.5	57
17	Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension, 2016, 67, 1273-1280.	2.7	57
18	Concentrations of Trace Elements and Clinical Outcomes in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 907-915.	4.5	54

#	Article	IF	CITATIONS
19	Serum Testosterone Levels and Clinical Outcomes in Male Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 268-275.	1.9	52
20	<i>UBD</i> modifies <i>APOL1</i> -induced kidney disease risk. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3446-3451.	7.1	52
21	The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2018, 72, 834-845.	1.9	51
22	First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1563-1568.	3.6	50
23	Effect of Race/Ethnicity on Hypertension Risk Subsequent to Gestational Diabetes Mellitus. American Journal of Cardiology, 2014, 113, 1364-1370.	1.6	44
24	Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney International, 2020, 97, 193-201.	5.2	44
25	MicroRNA-mediated mechanism of vitamin D regulation of innate immune response. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 81-86.	2.5	41
26	Vitamin D and Atherosclerotic Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4033-4050.	3.6	38
27	First-Trimester Follistatin-Like-3 Levels in Pregnancies Complicated by Subsequent Gestational Diabetes Mellitus. Diabetes Care, 2010, 33, 664-669.	8.6	36
28	Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease. American Journal of Nephrology, 2011, 33, 139-149.	3.1	36
29	Cohort Study of Severe Bronchiolitis during Infancy and Risk of Asthma by Age 5 Years. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 92-96.	3.8	35
30	Low-Molecular Weight Heparin Increases Circulating sFlt-1 Levels and Enhances Urinary Elimination. PLoS ONE, 2014, 9, e85258.	2.5	31
31	Calciphylaxis in peritoneal dialysis patients: a single center cohort study. International Journal of Nephrology and Renovascular Disease, 2016, Volume 9, 235-241.	1.8	31
32	Vitamin D: The More We Know, the Less We Know. Clinical Chemistry, 2015, 61, 462-465.	3.2	29
33	MENTAL HEALTH DISORDERS SUBSEQUENT TO GESTATIONAL DIABETES MELLITUS DIFFER BY RACE/ETHNICITY. Depression and Anxiety, 2015, 32, 774-782.	4.1	27
34	Vitamin D analogues to target residual proteinuria: potential impact on cardiorenal outcomes. Nephrology Dialysis Transplantation, 2015, 30, 1988-1994.	0.7	26
35	Vitamin D receptor activation: cardiovascular and renal implications. Kidney International Supplements, 2013, 3, 427-430.	14.2	24
36	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International, 2021, 100, 1199-1207.	5.2	23

#	Article	IF	CITATIONS
37	Vitamin D Toxicity. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 238-244.	0.9	22
38	Copy Number Variation at the APOL1 Locus. PLoS ONE, 2015, 10, e0125410.	2.5	17
39	Vitamin D and Calcimimetics in Cardiovascular Disease. Seminars in Nephrology, 2018, 38, 251-266.	1.6	16
40	Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial. Diabetologia, 2021, 64, 437-447.	6.3	16
41	Cross-sectional examination of metabolites and metabolic phenotypes in uremia. BMC Nephrology, 2015, 16, 98.	1.8	15
42	Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?. Journal of the American Society of Nephrology: JASN, 2009, 20, 2285-2290.	6.1	14
43	Vitamin D in Patients with Kidney Disease: Cautiously Optimistic. Advances in Chronic Kidney Disease, 2007, 14, 22-26.	1.4	13
44	Targeted ablation of the vitamin D $1\hat{l}\pm$ -hydroxylase gene: getting to the heart of the matter. Kidney International, 2008, 74, 141-143.	5.2	12
45	Impact of vitamin D on cardiac structure and function in chronic kidney disease patients with hypovitaminosis D: a randomized controlled trial and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 302-311.	3.0	12
46	Activated vitamin D sterols in kidney disease. Lancet, The, 2008, 371, 542-544.	13.7	11
47	Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population. Kidney International Reports, 2017, 2, 1042-1049.	0.8	11
48	Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. Nephron, 2018, 140, 265-274.	1.8	11
49	Affordable Preeclampsia Therapeutics. Trends in Pharmacological Sciences, 2019, 40, 85-87.	8.7	11
50	Long-Term Anticoagulation for Patients Receiving Dialysis. Circulation, 2018, 138, 1530-1533.	1.6	10
51	Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertension, 2016, 6, 333-339.	1.4	9
52	2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial. American Journal of Nephrology, 2017, 45, 40-48.	3.1	8
53	Hemodialysis Failure Secondary to Hydroxocobalamin Exposure. Baylor University Medical Center Proceedings, 2017, 30, 167-168.	0.5	7
54	Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (Retacrit TM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. American Journal of Nephrology, 2018, 48, 214-224.	3.1	7

#	Article	IF	CITATIONS
55	Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study. PLoS ONE, 2015, 10, e0124139.	2.5	6
56	Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics. Contemporary Clinical Trials, 2018, 74, 11-17.	1.8	6
57	Soluble Fms-Like Tyrosine Kinase 1 (sFlt-1) and Risk of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. World Neurosurgery, 2017, 108, 84-89.	1.3	5
58	Voriconazole-Induced Periostitis & Enthesopathy in Solid Organ Transplant Patients: Case Reports. Journal of Biosciences and Medicines, 2016, 04, 8-17.	0.2	5
59	Vitamin D–Binding Protein Deficiency and Homozygous Deletion of the GC Gene. New England Journal of Medicine, 2019, 380, 2582-2587.	27.0	4
60	Insulin Resistant Gestational Glucose Intolerance Is Associated With Adverse Perinatal Outcomes. Journal of the Endocrine Society, 2021, 5, A434-A434.	0.2	3
61	Serum phospholipid fraction of polyunsaturated fatty acids is the preferred indicator for nutrition and health status in hemodialysis patients. Journal of Nutritional Biochemistry, 2016, 38, 18-24.	4.2	2
62	Vitamin D for Cardiovascular Disease Prevention in Women: State of the Evidence. Current Cardiovascular Risk Reports, 2010, 4, 216-221.	2.0	1
63	Hypertension Risk Subsequent to Gestational Dysglycemia Is Modified by Race/Ethnicity. Hypertension, 2016, 67, 223-228.	2.7	1
64	Novel Preeclampsia Diagnostics and Real-World Applications. Hypertension, 2019, 74, 740-742.	2.7	1
65	Vitamin D, Hypertension, Left Ventricular Hypertrophy, and Diastolic Dysfunction. Current Cardiovascular Risk Reports, 2011, 5, 314-322.	2.0	0
66	The Authors Reply. American Journal of Epidemiology, 2014, 180, 758-758.	3.4	0
67	MP350VITAMIN D RECEPTOR ACTIVATION INCREASES SERUM SCLEROSTIN IN CKD PATIENTS: A RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2016, 31, i456-i456.	0.7	0
68	Phospholipid PUFA: a better indicator for assessing health risks. FASEB Journal, 2013, 27, 1072.16.	0.5	0